Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference

ALKS

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 29, 2021 at 8:40 a.m. ET (1:40 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-cantor-virtual-global-healthcare-conference-301382411.html

SOURCE Alkermes plc